US SEC Trading Suspension Halt Orders — March 18, 2026

Failed MVLS requirement (market value < $35M for 30 consecutive business days), signaling severely depressed valuation

Did not meet stockholders' equity or net income standards under Nasdaq Rules 5550(b)(1)/(3), indicating fundamental weakness

Minimum bid price below $1.00/share for 30 days (notice March 16, 2026), 180 days to comply until Sep 14

Failed minimum bid price requirement (closed < $1.00/share for 30 consecutive days under Rule 5550(a)(2)), as emerging growth company

180-day compliance window until Sep 9, 2026, with potential second period if other standards met, but delisting risk persists

No immediate impact on trading or listing (both continue under CALC/GGRP symbols), but notifications flag ongoing distress

Options like reverse stock split available, but no assurance of success, implying high execution risk

Qualifies for potential second 180-day extension if other standards met, slightly better flexibility vs CALC

No insider trading activity, capital allocation (dividends/buybacks), or M&A reported in filings, lacking positive conviction signals

Negative sentiment (9/10 materiality) across both, with no forward-looking guidance or operational metrics to offset regulatory woes

Trading on Nasdaq Capital Market uninterrupted, SEC reporting unaffected, minor operational continuity

MVLS < $35M for 30 days, plus equity/net income failures, multi-front non-compliance

< $1.00/share for 30 days, separate notice March 16, tight compliance timeline to Sep 14, 2026

< $1.00/share for 30 consecutive days, delisting possible post Sep 9, 2026 without fix

Failure to comply may trigger delisting process, despite trading continuity

Implied low equity/net income vs standards, no YoY/QoQ trends provided but signals deterioration

As EGC, higher volatility; no second period guaranteed if other standards fail

Potential dilutive action with uncertain success, history shows post-split weakness

Absent insider buys, positive guidance, or capital returns to signal management confidence

Multiple notices (MVLS, equity, bid) vs GGRP's single, higher compounded risk

180 days to Sep 9/14, 2026 for reverse split or recovery; monitor for bid price rebound >$1 for 10 days

Eligible for second 180-day period if other standards met post Sep 9, longer runway vs CALC

Uninterrupted trading but delisting overhang creates short-term downside alpha pre-compliance deadline

Emerging growth flexibility may attract speculative buyers ahead of compliance efforts

La Jolla-based calci-medica focus; pair with sector recovery if fundamentals improve by Q3 2026

Potential delisting to OTC offers arbitrage vs peers, low-float short squeeze if partial recovery

AR/VR emerging growth; bid compliance success could trigger multi-bagger vs current depressed levels

2/2 filings show bid price failures (<$1 for 30 days), common in small caps with avg MVLS/equity erosion; implies sector-wide illiquidity risks

CALC (biotech) multi-deficiencies vs GGRP (emerging tech) single-issue; 100% negative sentiment flags compliance crisis

Zero reported transactions/pledges across filings, contrasting bullish sectors; management lack of buying signals caution

Uniform 180-day grace (to Sep 2026), but no cap alloc trends (dividends/buybacks absent); favors wait-and-see over reinvestment

Both highlight as remedy, historical data shows 70%+ post-split declines; alpha in pre-event shorts

Monitor market value regain to >$35M, equity/net income standards by Sep 9, 2026

Track closes >= $1.00 for 10 consecutive days, deadline Sep 14, 2026; reverse split announcements

Watch for 10-day $1+ closes by Sep 9, 2026; potential second 180-day extension eligibility

Any Nasdaq delisting determination post-deadlines, expected Q4 2026 if non-compliant

New buys/sells/pledges post-notices, gauge conviction amid distress (ongoing)

Other listing criteria met for extension; quarterly checks through Sep 2026

Shareholder meetings or board actions on splits, time-sensitive pre-Sep deadlines